Form 8-K - Current report:
SEC Accession No. 0001213900-25-111298
Filing Date
2025-11-17
Accepted
2025-11-17 08:50:42
Documents
14
Period of Report
2025-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0265959-8k_oramed.htm   iXBRL 8-K 38754
2 RIGHTS AGREEMENT, DATED AS OF NOVEMBER 17, 2025, BETWEEN ORAMED PHARMACEUTICALS ea026595901ex4-1_oramed.htm EX-4.1 243430
3 PRESS RELEASE DATED NOVEMBER 17, 2025 ea026595901ex99-1_oramed.htm EX-99.1 9039
  Complete submission text file 0001213900-25-111298.txt   514909

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ormp-20251116.xsd EX-101.SCH 3008
5 XBRL LABEL FILE ormp-20251116_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ormp-20251116_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0265959-8k_oramed_htm.xml XML 3688
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 251489482
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)